Compare AbCellera Biologics Inc (ABCL) vs Etsy Inc (ETSY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Etsy Inc — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while Etsy Inc trades at $76.49 (market cap $7.36B). The key difference: Etsy Inc is far larger — about 3.1× AbCellera Biologics Inc's market cap. Which is the better fit depends on your goals.
| ABCL | ETSY | |
|---|---|---|
Market Cap | $2.35B | $7.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $79.66 |
52-Week Low | $2.78 | $44.05 |
Enterprise Value | $1.99B | $9.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
ETSY trades at $77.59, up 0.81% today, with a bullish technical signal from moving averages and support at $74. The company reported three consecutive quarterly earnings beats, with Q1 2026 EPS of $0.89 beating expectations of $0.62 (Seeking Alpha, 2026-05-29). Revenue for 2025 was $2.88B, though net income declined to $163M. Analyst consensus is a Buy with a $70.79 price target, and recent news highlights growth in AI seller tools and buyer recovery momentum.
ETSY shows potential with strong profitability margins and positive cash flow trends, but faces risks from high debt and competitive pressures. The stock's valuation multiples like P/E of 28.76 suggest moderate premium, while institutional sentiment remains cautiously optimistic amid execution challenges in sustaining growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →
